thumbnail_EVAxKSA-al-dawaa-part-web2.png

EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_1704997569480.jfif

1704997569480.jfif

Life at EVA Pharma

·Riyadh, Saudi Arabia — October 23, 2024,&nbsp;EVA Pharma&nbsp;one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has signed an agreement with Al-Dawaa Medical Services Company to strengthen their collaboration and provide high quality pharmaceuticals in the Saudi market. This partnership aims to ensure sustainable access to essential medicines and meet the healthcare needs of citizens.
The&nbsp;agreement was signed today on the sidelines of the Global Health Exhibition in Riyadh. Within the collaboration, both parties will work to improve the availability of high-quality medicines by developing logistics services and optimizing reliance on digital transformation to ensure that production and distribution adhere to the highest quality standards. Additionally, EVA Pharma and AlDawaa will provide accurate information about the medications to educate people about diseases and available treatments, maximizing the impact on the quality of life.
The partnership will also include developing proactive strategies aimed at addressing any challenges that could hinder the manufacturing or supply of medicines, while ensuring affordable prices for the local market, maintaining a steady supply, and ensuring the stability of the Saudi market.
Dr. Amgad Talaat, Regional Director of EVA Pharma Saudi Arabia and Director of Strategic Alliances, said that&nbsp;the collaboration between the two companies is part of EVA Pharma's commitment to expanding the localization of pharmaceutical and medicine manufacturing in Saudi Arabia.&nbsp;"This effort includes a series of major achievements, such as the establishment of our advanced industrial complex&nbsp;for research and manufacturing in Sudair Industrial City and the opening of EVA Pharma’s scientific office in Riyadh, in addition to collaborating with various entities to facilitate the availability of high-quality advanced medicines at affordable prices for Saudi patients."
&nbsp;
Mr.&nbsp;Fahd Al-Faraj, Executive Vice President of Al-Dawaa Medical Services Company,&nbsp;emphasized Al-Dawaa’s commitment to leveraging its capabilities and its dedication to forming fruitful partnerships to serve a large number of patients by making the medications manufactured by EVA Pharma available in the Kingdom. He also stressed the importance of supporting all efforts to localize advanced industries in Saudi Arabia in line with Vision 2030's goals for developing the healthcare sector.
This cooperation comes as part of efforts to support the healthcare sector in the Kingdom, in line with Saudi Vision 2030, which aims to enhance healthcare development and achieve self-sufficiency in the pharmaceutical sector.
--End of Press Release--
&nbsp;About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa while operating in more than 70 countries worldwide. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
For more information, please visit: <a href="https://www.evapharma.com/en-SA">https://www.evapharma.com/en-SA</a> or follow us on <a href="https://twitter.com/EVAPharma_MEA">X</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/evapharma_middle_east/" target="_blank" rel="noopener">Instagram</a> &nbsp;
&nbsp;
<div style="mso-element: endnote-list;">
<div id="edn1" style="mso-element: endnote;"></div>
</div>

Press Release

EVA Pharma Collaborates with Al-Dawaa to Provide Sustainable Access to High-Quality Medicines in the Saudi Market

Are you a Healthcare professional?

EVA Pharma Collaborates with Al-Dawaa to Provide Sustainable Access to High-Quality Medicines in the Saudi Market

22 Oct, 2024

EVA Pharma Collaborates with Al-Dawaa to Provide Sustainable Access to High-Quality Medicines in the Saudi Market

22 Oct, 2024

Find out more about EVA Pharma

EVA Pharma’s roots stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.